Medicine
Tumor Mutational Burden and Response to Immune Checkpoint Inhibitors
Quick fact
Tumors with more than 10 mutations per megabase of DNA are often considered 'TMB-high' and are more likely to respond to checkpoint inhibitors, regardless of cancer type.
Why this is interesting
You’ve probably heard that immunotherapy can cure some cancers, but why does it fail in others? The answer may lie in the tumor’s mutation count.